Pfizer-Pharmawert total unterbewertet! 50% möglich! (Seite 11)
eröffnet am 15.05.06 13:00:41 von
neuester Beitrag 08.05.24 23:27:36 von
neuester Beitrag 08.05.24 23:27:36 von
Beiträge: 2.477
ID: 1.060.098
ID: 1.060.098
Aufrufe heute: 65
Gesamt: 331.836
Gesamt: 331.836
Aktive User: 0
ISIN: US7170811035 · WKN: 852009 · Symbol: PFE
26,01
EUR
-1,16 %
-0,31 EUR
Letzter Kurs 12:01:32 Tradegate
Neuigkeiten
07.05.24 · inv3st.de Anzeige |
06.05.24 · Business Wire (engl.)  |
03.05.24 · Felix Haupt Anzeige |
02.05.24 · dpa-AFX Analysen |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8450 | +146,00 | |
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9235 | -16,88 | |
| 5,2500 | -19,23 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ein kleiner weiterer Schritt bei der Therapieentwicklung gegen Gebärmutterhals-Krebs:
https://seekingalpha.com/news/4061950-pfizer-genmab-cervical…
https://seekingalpha.com/news/4061950-pfizer-genmab-cervical…
Antwort auf Beitrag Nr.: 75.207.200 von hafripo am 02.02.24 11:32:23So machen wir das 
Ich kaufe gerne solche "out of favoir stocks". Verkaufen kann man denn, wenn sich wieder alle darum reißen. Bin ja ein gutherziger Kerl.
Ich kaufe gerne solche "out of favoir stocks". Verkaufen kann man denn, wenn sich wieder alle darum reißen. Bin ja ein gutherziger Kerl.
„Pfizer (PFE) is out of favor due to disappointing financial results for the company’s Covid-19 and respiratory syncytial virus (RSV) vaccines.
However, Pfizer could stage a comeback with treatments targeting cancer and obesity.
Investors should buy PFE stock and reinvest the dividend distributions.“
https://investorplace.com/2024/02/pfizers-2024-comeback-a-di…
However, Pfizer could stage a comeback with treatments targeting cancer and obesity.
Investors should buy PFE stock and reinvest the dividend distributions.“
https://investorplace.com/2024/02/pfizers-2024-comeback-a-di…
Antwort auf Beitrag Nr.: 75.186.632 von Nordsturm am 30.01.24 11:07:12
Meta war ein Volltreffer. 🙂
Zitat von Nordsturm:Zitat von bcgk: ...
Deine Top 5 in dieser Hinsicht fände ich spannend. Vielen Dank Nordsturm.
Meine persönliche Top 3 ist derzeit:
-Hormel Foods (ähnlicher Verlauf wie Pfizer, gute Dividende und weniger Risk aber größeres Potential wieder Richtung ATH zu wandern)
-Kinder Morgan (perfekter Dividenden-Wert mit guter Stabilität)
-Meta Platforms (Digital Humid wird kommen, davon bin ich überzeugt! Noch riesiges Wachstumspotential)
Im Pharma Sektor setze ich derzeit eher auf J&J und Abbvie (nach den Zahlen)
Meta war ein Volltreffer. 🙂
Antwort auf Beitrag Nr.: 75.196.379 von Durando am 31.01.24 19:35:44Pfizer bleibt ein klarer Kauf auf dem Niveau. Sparplan läuft parallel zur $28 Einstiegsposition.
Trading Spotlight
https://ca.investing.com/news/stock-market-news/earnings-cal…
„Pfizer Inc. (NYSE:PFE) has reported a mixed financial performance in its Fourth Quarter 2023 Earnings Conference Call, with CEO Albert Bourla outlining the company's strategic priorities for the upcoming year. Despite a significant drop in COVID-19 product sales, Pfizer achieved operational revenue growth and impacted over 620 million lives globally in 2023. The pharmaceutical giant also detailed its focus on oncology, pipeline innovation, and cost realignment to enhance shareholder value.
Key Takeaways
Pfizer reported a 41% operational decrease in COVID product sales year-over-year.
The company achieved 7% operational revenue growth in 2023, with total revenues reaching $58.5 billion.
Diluted EPS for the year declined by 93%, primarily due to lower sales of COVID-19 vaccine Comirnaty and treatment Paxlovid.
Pfizer has become the top pharmaceutical company in revenue from pharma-only products and had a record year for FDA approvals.
The company's strategic priorities for 2024 include oncology leadership, pipeline innovation, maximizing new product performance, cost realignment, and shareholder value enhancement.
Company Outlook
Pfizer expects to drive growth potential in the latter half of the decade.
The company aims for world-class oncology leadership and to maintain a robust pipeline across various therapeutic areas.
Pfizer is focused on maximizing the performance of new products and core franchises, including efforts to grow key blockbusters.
Bearish Highlights
The decline in COVID product sales has significantly affected year-over-year operational revenue.
Comirnaty sales are not expected to significantly increase in the future, except potentially through co-administration with flu vaccines.
The pediatric market for Prevnar is progressing well, but the adult market faces challenges due to a smaller patient population and increased competition.
Bullish Highlights
Pfizer aims to achieve $10 billion in revenue from its oncology franchise by 2030.
The company sees significant opportunities in international markets, such as China, Japan, Germany, and France.
Pfizer's next-generation PCV vaccine is expected to maintain the pneumonia claim from the CAPiTA trial.
Misses
Diluted EPS declined significantly due to lower sales of COVID-19 related products.
Q&A Highlights
R&D expenses were favorable due to cost realignment and timing implications.
Pfizer aims to achieve net savings of $4 billion, with half already achieved by the end of 2023.
The company did not provide updates on Danuglipron but plans to share more data on their RSV vaccine, Abrysvo, in Q2 2024.
No comment was made on the expected ACIP recommendation regarding Prevnar and VV116.
Pfizer's financial results reflect the changing landscape of the pharmaceutical industry, as the demand for COVID-19 related products decreases. However, the company's strategic focus on areas such as oncology, vaccine development, and international market expansion signals confidence in its long-term growth potential. Pfizer's commitment to delivering innovative treatments and maintaining strong financial discipline is poised to continue driving its performance in the coming years.
InvestingPro Insights
Pfizer Inc. (PFE) has navigated through a transformative period as COVID-19 product sales wane, yet it continues to show resilience with a focus on operational revenue growth and strategic priorities. The latest insights from InvestingPro provide a deeper look into the company's financial health and market position.
InvestingPro Data indicates a market capitalization of $154.26 billion, reflecting the company's significant presence in the pharmaceutical industry. Despite a challenging year marked by a revenue decline of 31.38% over the last twelve months as of Q1 2023, Pfizer has managed to maintain a Gross Profit Margin of 68.99%, showcasing its ability to retain profitability amidst revenue fluctuations.
Diving deeper into the company's financial metrics, an Adjusted P/E Ratio of 8.47 suggests that the stock may be undervalued relative to its earnings, which could appeal to value investors. Additionally, Pfizer's Dividend Yield stands at an attractive 6.22%, complemented by its reputation for consistent dividend payments, having raised its dividend for 13 consecutive years and maintained payments for 54 years.
InvestingPro Tips highlight that Pfizer is a prominent player in the Pharmaceuticals industry, with analysts revising their earnings upwards for the upcoming period, indicating potential optimism about the company's future performance. Moreover, it is noted that Pfizer's stock generally trades with low price volatility, which might be a reassuring factor for investors seeking stability.
For those interested in further detailed analysis and additional tips, InvestingPro offers more insights on Pfizer, with a total of 14 InvestingPro Tips available. Subscribers can access these tips and more by visiting https://www.investing.com/pro/PFE.
To take advantage of the special New Year sale, subscribers can get up to 50% off on an InvestingPro subscription. Use coupon code SFY24 for an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 for an additional 10% off a 1-year InvestingPro+ subscription.
Pfizer's commitment to its strategic priorities, such as oncology leadership and pipeline innovation, combined with its financial discipline and operational growth, positions the company to potentially overcome the current challenges and capitalize on future opportunities.“
„Pfizer Inc. (NYSE:PFE) has reported a mixed financial performance in its Fourth Quarter 2023 Earnings Conference Call, with CEO Albert Bourla outlining the company's strategic priorities for the upcoming year. Despite a significant drop in COVID-19 product sales, Pfizer achieved operational revenue growth and impacted over 620 million lives globally in 2023. The pharmaceutical giant also detailed its focus on oncology, pipeline innovation, and cost realignment to enhance shareholder value.
Key Takeaways
Pfizer reported a 41% operational decrease in COVID product sales year-over-year.
The company achieved 7% operational revenue growth in 2023, with total revenues reaching $58.5 billion.
Diluted EPS for the year declined by 93%, primarily due to lower sales of COVID-19 vaccine Comirnaty and treatment Paxlovid.
Pfizer has become the top pharmaceutical company in revenue from pharma-only products and had a record year for FDA approvals.
The company's strategic priorities for 2024 include oncology leadership, pipeline innovation, maximizing new product performance, cost realignment, and shareholder value enhancement.
Company Outlook
Pfizer expects to drive growth potential in the latter half of the decade.
The company aims for world-class oncology leadership and to maintain a robust pipeline across various therapeutic areas.
Pfizer is focused on maximizing the performance of new products and core franchises, including efforts to grow key blockbusters.
Bearish Highlights
The decline in COVID product sales has significantly affected year-over-year operational revenue.
Comirnaty sales are not expected to significantly increase in the future, except potentially through co-administration with flu vaccines.
The pediatric market for Prevnar is progressing well, but the adult market faces challenges due to a smaller patient population and increased competition.
Bullish Highlights
Pfizer aims to achieve $10 billion in revenue from its oncology franchise by 2030.
The company sees significant opportunities in international markets, such as China, Japan, Germany, and France.
Pfizer's next-generation PCV vaccine is expected to maintain the pneumonia claim from the CAPiTA trial.
Misses
Diluted EPS declined significantly due to lower sales of COVID-19 related products.
Q&A Highlights
R&D expenses were favorable due to cost realignment and timing implications.
Pfizer aims to achieve net savings of $4 billion, with half already achieved by the end of 2023.
The company did not provide updates on Danuglipron but plans to share more data on their RSV vaccine, Abrysvo, in Q2 2024.
No comment was made on the expected ACIP recommendation regarding Prevnar and VV116.
Pfizer's financial results reflect the changing landscape of the pharmaceutical industry, as the demand for COVID-19 related products decreases. However, the company's strategic focus on areas such as oncology, vaccine development, and international market expansion signals confidence in its long-term growth potential. Pfizer's commitment to delivering innovative treatments and maintaining strong financial discipline is poised to continue driving its performance in the coming years.
InvestingPro Insights
Pfizer Inc. (PFE) has navigated through a transformative period as COVID-19 product sales wane, yet it continues to show resilience with a focus on operational revenue growth and strategic priorities. The latest insights from InvestingPro provide a deeper look into the company's financial health and market position.
InvestingPro Data indicates a market capitalization of $154.26 billion, reflecting the company's significant presence in the pharmaceutical industry. Despite a challenging year marked by a revenue decline of 31.38% over the last twelve months as of Q1 2023, Pfizer has managed to maintain a Gross Profit Margin of 68.99%, showcasing its ability to retain profitability amidst revenue fluctuations.
Diving deeper into the company's financial metrics, an Adjusted P/E Ratio of 8.47 suggests that the stock may be undervalued relative to its earnings, which could appeal to value investors. Additionally, Pfizer's Dividend Yield stands at an attractive 6.22%, complemented by its reputation for consistent dividend payments, having raised its dividend for 13 consecutive years and maintained payments for 54 years.
InvestingPro Tips highlight that Pfizer is a prominent player in the Pharmaceuticals industry, with analysts revising their earnings upwards for the upcoming period, indicating potential optimism about the company's future performance. Moreover, it is noted that Pfizer's stock generally trades with low price volatility, which might be a reassuring factor for investors seeking stability.
For those interested in further detailed analysis and additional tips, InvestingPro offers more insights on Pfizer, with a total of 14 InvestingPro Tips available. Subscribers can access these tips and more by visiting https://www.investing.com/pro/PFE.
To take advantage of the special New Year sale, subscribers can get up to 50% off on an InvestingPro subscription. Use coupon code SFY24 for an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 for an additional 10% off a 1-year InvestingPro+ subscription.
Pfizer's commitment to its strategic priorities, such as oncology leadership and pipeline innovation, combined with its financial discipline and operational growth, positions the company to potentially overcome the current challenges and capitalize on future opportunities.“
https://www.contractpharma.com/contents/view_breaking-news/2…
„4Q Revenues: $14.2 billion (-41%)
4Q Loss: $3.4 billion (earnings were $5.0 billion 4Q22)
FY Revenues: $58.5 billion (-42%)
FY Earnings: $2.1 billion (-93%)
Comments: Decline in Comirnaty and Paxlovid revenues drove 42% operational decrease in the quarter. Biopharmaceuticals business sales were down 42% in the quarter to $13.9 billion.
Primary Care sales were down 60% to $7.0 billion. Specialty care sales were up 11% to $3.9 billion. Oncology sales were down 3% to $2.9 billion in the quarter.
Abrysvo contributed $515 million in global revenues in the quarter, driven primarily by launch of the older adult indication in the U.S. in July 2023. Vyndaqel family sales were up 39% operationally, driven largely by continued uptake of the transthyretin amyloid cardiomyopathy (ATTR-CM) indication. Global Eliquis sales were up 9% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication, partially offset by declines due to loss of exclusivity and generic competition in certain international markets.
Global Ibrance sales were down 13% operationally, driven primarily by lower demand globally due to competition and lower clinical trial purchases in certain international markets.
Global Prevnar family sales were down 7% operationally, driven primarily by the pediatric indication in emerging markets due to lower demand and unfavorable timing of customer orders.
R&D expenses were $2.8 billion in the quarter, down 22%.“
„4Q Revenues: $14.2 billion (-41%)
4Q Loss: $3.4 billion (earnings were $5.0 billion 4Q22)
FY Revenues: $58.5 billion (-42%)
FY Earnings: $2.1 billion (-93%)
Comments: Decline in Comirnaty and Paxlovid revenues drove 42% operational decrease in the quarter. Biopharmaceuticals business sales were down 42% in the quarter to $13.9 billion.
Primary Care sales were down 60% to $7.0 billion. Specialty care sales were up 11% to $3.9 billion. Oncology sales were down 3% to $2.9 billion in the quarter.
Abrysvo contributed $515 million in global revenues in the quarter, driven primarily by launch of the older adult indication in the U.S. in July 2023. Vyndaqel family sales were up 39% operationally, driven largely by continued uptake of the transthyretin amyloid cardiomyopathy (ATTR-CM) indication. Global Eliquis sales were up 9% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication, partially offset by declines due to loss of exclusivity and generic competition in certain international markets.
Global Ibrance sales were down 13% operationally, driven primarily by lower demand globally due to competition and lower clinical trial purchases in certain international markets.
Global Prevnar family sales were down 7% operationally, driven primarily by the pediatric indication in emerging markets due to lower demand and unfavorable timing of customer orders.
R&D expenses were $2.8 billion in the quarter, down 22%.“
Antwort auf Beitrag Nr.: 75.192.974 von cure am 31.01.24 11:28:56
Das kann man so sehen, aber man war halt von Pfizer Jahre lang, bessere Quartalszahlen gewöhnt.
Es wundert mich etwas, dass der Umsatz und der Gewinn so stark von Comirnaty und Paxlovid abhängen ?
Aber immerhin gab es ja starke Sondereffekte, wodurch es immerhin noch einen relativ kleinen Gewinn gab.
Ich bleibe auch investiert, der Kurs ist viel zu niedrig, um etwas zu verkaufen.
Und die Dividende ist ja bisher gut.
Zitat von cure: man muss die Zahlen halt zum aktuellen Kurs sehen ...und dann relativiert sich das mit den Zahlen die ""nicht so toll"" waren ...für"s 10 Jahrestief sind die Zahlen nämlich zu gut ... und die Stellschrauben sind ja gefunden und werden justiert ...will sagen ...mE gute BuyandholdKurse ...
Das kann man so sehen, aber man war halt von Pfizer Jahre lang, bessere Quartalszahlen gewöhnt.
Es wundert mich etwas, dass der Umsatz und der Gewinn so stark von Comirnaty und Paxlovid abhängen ?
Aber immerhin gab es ja starke Sondereffekte, wodurch es immerhin noch einen relativ kleinen Gewinn gab.
Ich bleibe auch investiert, der Kurs ist viel zu niedrig, um etwas zu verkaufen.
Und die Dividende ist ja bisher gut.
Antwort auf Beitrag Nr.: 75.192.704 von Durando am 31.01.24 10:59:18
Das ist bei solch großen Unternehmen in der Tat eine effektive Stellenschraube.
Zitat von Durando: Die Zahlen waren wirklich nicht so toll.
Pfizer will aber die Kosten deutlich reduzieren, was sich wahrscheinlich schon in diesem Jahr positiv auf die Bilanz auswirken wird.
Das ist bei solch großen Unternehmen in der Tat eine effektive Stellenschraube.
Antwort auf Beitrag Nr.: 75.192.704 von Durando am 31.01.24 10:59:18man muss die Zahlen halt zum aktuellen Kurs sehen ...und dann relativiert sich das mit den Zahlen die ""nicht so toll"" waren ...für"s 10 Jahrestief sind die Zahlen nämlich zu gut ... und die Stellschrauben sind ja gefunden und werden justiert ...will sagen ...mE gute BuyandholdKurse ...
Durchsuchen
01.05.24 · dpa-AFX · Amazon |
01.05.24 · dpa-AFX · Amazon |
01.05.24 · dpa-AFX · Pfizer |
01.05.24 · dpa-AFX · Advanced Micro Devices |
01.05.24 · dpa-AFX · Advanced Micro Devices |
